Researchers at Infixion Bioscience are on a mission to develop new therapeutics for the “orphan disease” neurofibromatosis type 1, which is diagnosed at a rate 1 in 3000 live births, impacting millions across the globe.  Neurofibromatosis type 1 is a genetic disorder...

A decade ago, in vivo antibody discovery relied heavily on wild-type mice. Today, it’s not uncommon to generate antibodies using a petting zoo of animals including chicken, goat, rabbit, llamas, alpacas, and humanized rodents. The immune responses of these animals...

Next-generation sequencing (NGS) has allowed for unprecedented insights into patterns of the immune response. It can enable high-throughput sequencing of hybridomas as we have discussed in NGS-Enhanced antibody discovery blog post and resource pages. NGS can provide a...

Abterra Bio uses bioinformatics and mass spectrometry to reconstructs the full amino acid sequence of both antibody chains. We’ve successfully sequenced human, mouse, rat, hamster, rabbit, and llama antibodies. This approach can be applied across any species and...

Immune repertoire sequencing enables deeper understanding of the adaptive immune response [1].  Abterra Biosciences has developed Reptor™, a flexible immune repertoire sequencing and analysis service. In this study, we analyzed the B-cell receptor (BCR) repertoire...

Abterra Bio uses next-generation sequencing to mine the clonal lineage of serum-identified antibodies. This method rescues relatives of hits that are within a clone and increases diversity in your antibody discovery campaign.  Contact us to learn more about how our...

Alicanto® is Abterra Biosciences' proprietary antibody discovery platform that mines the entire immune response to identify diverse, functional antibodies. For an overview of the proteogenomic process, read more about Alicanto®. The infographic below was created using...